Hims & Hers Health, Inc.

As of June 30, 2026, Hims & Hers Health, Inc. Class A carries a market capitalization of 139.97B, placing it among publicly traded companies globally. Its enterprise value stands at 152.29B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Hims & Hers Health, Inc. Class A's next confirmed earnings release is scheduled for November 9, 2026.

As of June 30, 2026, Hims & Hers Health, Inc. Class A has 233.30M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 3.04, and the price-to-book ratio stands at 24.72.

These figures are as of June 30, 2026. The EV/Sales ratio of 3.38 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 152.29B versus a market cap of 139.97B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Hims & Hers Health, Inc. Class A maintains a current ratio of 0.93, meaning it holds 0.9x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, Hims & Hers Health, Inc. Class A posted a negative return on equity (ROE) of -32.03, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -5.16, reflecting losses generated across the asset base. The company generates approximately 20.10M in revenue per employee across its workforce of 2,240.75, a quick read on workforce productivity versus industry peers. Inventory turnover of 7.09 indicates how many times Hims & Hers Health, Inc. Class A sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Hims & Hers Health, Inc. Class A recorded an income tax benefit of -377.00M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -2.86B and -2.48B in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, Hims & Hers Health, Inc. Class A's stock has declined approximately 38.94% over the past 52 weeks. The 50-day moving average sits at 511.83, while the 200-day moving average is 475.02.

Over the twelve months ended June 30, 2026, Hims & Hers Health, Inc. Class A generated 45.04B in revenue and converted that into -2.48B in net income, yielding earnings per share of -10.37. EBITDA reached -1.18B, while operating income came in at -2.70B.

As of June 30, 2026, Hims & Hers Health, Inc. Class A holds 14.69B in cash and equivalents against 27.02B in total debt, resulting in a net debt position of 13.20B. Total book value stands at 5.66B, with working capital of -1.72B providing operational flexibility.

Hims & Hers Health, Inc. Class A produced 4.60B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -3.53B in capital expenditures, free cash flow totaled 1.08B - equivalent to 4.72 per share.

Over the twelve months ended June 30, 2026, Hims & Hers Health, Inc. Class A posted a gross margin of 68.43, reflecting its pricing power and cost economics. The operating margin of -5.99 and net profit margin of -5.51 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield stands at 0.75, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield is negative at -1.59, meaning Hims & Hers Health, Inc. Class A raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of June 30, 2026, Hims & Hers Health, Inc. Class A has an Altman Z-Score of 2.19, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.